Pharmaceutical Companies Gird for Drug-Price Reckoning
Uproar over suddenly hiked-up medications may not crush health care stocks for long, but it does force the industry to justify value.
Kaitlin Ugolik
October 8, 2015
Martin Shkreli, chief investment officer of MSMB Capital Management, sits behind a chess board in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited, $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker’s top management if successful. Photographer: Paul Taggart/Bloomberg
Paul Taggart/Bloomberg
